secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-050227
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Allogene Therapeutics Reports Q3 2025 Net Loss of $41.4M, Cash of $277.1M
-------------------------------------------------------------------------

- Q3 2025 net loss $41.4M ($0.19 per share), cash $277.1M, cash runway into 2H 2027.
- Phase 2 ALPHA3 trial for cema-cel in LBCL on track for futility analysis in 1H 2026.
- Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease enrolling, proof-of-concept data expected 1H 2026.
- Phase 1 TRAVERSE trial for ALLO-316 in RCC shows durable responses; next phase under evaluation.
- Additional ALPHA3 trial sites in Australia and South Korea expected to open early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000162828025050227/0001628280-25-050227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000162828025050227/allo-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-050227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer